Retatrutide

Retatrutide 10 mg is offered by SARMs Revolution Lab for laboratory research in Canada. This page separates published evidence from product information so researchers can understand what the molecule is, what has actually been studied, and where important evidence gaps remain.

Buy Retatrutide 10 mg in Canada for Laboratory Research

SRL supplies a 10 mg Retatrutide research vial with discreet Canadian shipping. The 10 mg designation identifies the stated quantity of material in the vial; it is not a dosage recommendation. Researchers should verify the current lot documentation and follow their institution’s handling, storage, safety and disposal procedures.

• Product: Retatrutide research peptide
• Stated vial quantity: 10 mg
• Research context: laboratory and analytical work only
• Shipping: discreet delivery within supported Canadian regions
• Human or veterinary use: not intended or authorized

What Is Retatrutide?

Retatrutide, also identified in the scientific literature as LY3437943, is an investigational triple receptor agonist. It was designed to activate the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. That three-receptor profile distinguishes it from single-pathway GLP-1 compounds and dual GIP/GLP-1 agonists.

The published research concerns a defined investigational pharmaceutical candidate used under controlled clinical-trial conditions. Those results must not be treated as proof of the identity, purity, safety or effectiveness of any independently sold research vial.

How Is Triple-Receptor Activity Studied?

Researchers study the three pathways because they participate in different but overlapping aspects of metabolic regulation. GLP-1 and GIP signalling are associated with nutrient-responsive endocrine activity, while glucagon-receptor activity is studied in relation to hepatic energy regulation and expenditure. Retatrutide provides a model for examining how simultaneous signalling may differ from activating one pathway alone.

Mechanistic hypotheses are not clinical guarantees. Receptor activity, formulation, exposure, study population and trial design all affect how results should be interpreted.

What Has Published Research Reported?

A 2023 phase 2, double-blind, randomized, placebo-controlled trial enrolled 338 adults and evaluated Retatrutide over 48 weeks. The investigators reported dose-dependent changes in body weight, with the largest mean reduction reported in the 12 mg trial group. Gastrointestinal adverse events were the most common, and dose-dependent increases in heart rate were also reported. The study was funded by Eli Lilly and registered as NCT04881760.

These findings are scientifically important, but they have clear limits:

• They describe a controlled clinical-trial product and protocol, not SRL material.
• One phase 2 study cannot settle long-term safety, comparative effectiveness or performance outside the trial population.
• Results in humans do not create instructions for self-experimentation or unsupervised use.
• Ongoing or later trials should be reviewed before drawing current regulatory conclusions.

Retatrutide Research Status in Canada

SRL markets this vial strictly as research material and not as an approved medication, supplement or treatment. This page does not provide medical advice, dosing, reconstitution or administration instructions. Researchers and institutions remain responsible for checking current Canadian requirements, ethics rules and laboratory controls applicable to their work.

Retatrutide 10 mg Quality Questions to Review

Before using any research material, confirm that the documentation matches the exact lot and product received. Relevant checks can include identity, stated quantity, analytical method, reported purity, date, lot number and laboratory attribution. A generic marketing statement is not a substitute for batch-specific evidence.

Frequently Asked Questions About Retatrutide

What is the difference between Retatrutide and Semaglutide?

Retatrutide is studied as a GIP, GLP-1 and glucagon receptor agonist, while Semaglutide primarily targets the GLP-1 receptor. They are different molecules with different evidence bases and should not be treated as interchangeable.

Is this Retatrutide vial approved for human use?

No. SRL offers this product only for laboratory research and analytical testing. It is not sold as a medicine and is not intended for human consumption, self-administration, diagnosis, treatment or veterinary use.

What does 10 mg mean on the Retatrutide vial?

It is the stated total quantity of material in the vial. It does not describe a dose, protocol or frequency of use.

How should a Retatrutide research vial be stored?

Storage requirements can depend on formulation and lot-specific stability information. Researchers should rely on the current product documentation and their institutional laboratory protocol rather than a generic instruction copied from another peptide.

Does SRL provide Retatrutide dosing or reconstitution instructions?

No. Providing those instructions would conflict with the research-only status of the product. This page is limited to product identification, scientific context and evidence limitations.

Where can researchers compare related peptide pathways?

See the Semaglutide research page for GLP-1-specific context, or browse the complete Canadian research peptide catalogue.

Scientific References

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023.
2. ClinicalTrials.gov record NCT04881760.

Research-use notice: Retatrutide 10 mg is offered strictly for laboratory research and in-vitro analytical work. It is not intended for human consumption, self-administration, diagnosis, treatment or veterinary use. No dosage, reconstitution or administration instructions are provided or implied.